Nuformix plc
Result of Annual General Meeting
The Annual General Meeting of Nuformix plc was held on 19th September 2018 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street,
The Directors of the Company wish to announce that all the resolutions were passed by the required majority. The results of the voting by poll on the resolutions put to the meeting are listed below.
|
|
Resolution |
Ordinary/ Special |
For* |
|
Against |
|
Total votes cast |
|
|
|
|
No. of votes |
% |
No. of votes |
% |
|
|
1 |
To receive the annual report and accounts for the year ended 31 March 2018
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
2 |
To approve the Directors' Remuneration Policy
|
Ordinary |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
3 |
To approve the Annual Report on Remuneration
|
Ordinary |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
4 |
To re-appoint David Tapolczay as a director
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
5 |
To re-appoint Daniel Gooding as a director
|
Ordinary |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
6 |
To re-appoint Joanne Holland as a director
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
7 |
To re-appoint John Lidgey as a director
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
8 |
To re-appoint Kirk Siderman-Wolter as a director
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
9 |
To re-Christopher Blackwell as a director
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
10 |
To re-appoint haysmacintyre as auditor
|
Ordinary |
141,656,903 |
100 |
0 |
0 |
141,656,903 |
|
11 |
To authorise the Directors to determine the auditor's fees.
|
Ordinary |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
12 |
To authorise the Directors to allot shares.
|
Ordinary |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
13 |
To authorise the Directors to disapply pre-emption rights.
|
Special |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
14 |
To authorise the Company to purchase its own shares.
|
Special |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
|
15 |
To authorise calling of a general meeting on 14 clear days' notice.
|
Special |
134,767,823 |
95.14 |
6,889,080 |
4.86 |
141,656,903 |
*The 'For' votes include those votes giving the Chairman discretion.
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 460,750,000 ordinary shares of 0.1p each.
Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.
19 September 2018
For further information please contact:
|
Nuformix plc Dr Dan Gooding, Chief Executive Officer |
+44 (0)1223 423667
|
|
Gable Communications Ltd John Bick / Justine James |
+44 (0)20 7193 7463
|
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.